Please login to the form below

roxadustat

This page shows the latest roxadustat news and features for those working in and with pharma, biotech and healthcare.

Astellas files new application for expanded use of roxadustat in Japan

Astellas has set its sights on extending the use of roxadustat into Japan, for the treatment of anaemia associated with chronic kidney disease (CKD) in non-dialysis patients. . ... Together with partner FibroGen, Astellas has submitted a supplemental

Latest news

GSK files anaemia drug daprodustat in Japan, its first market

Another oral HIF-PHI drug – AstraZeneca and FibroGen’s roxadustat– has already been approved in China for CKD anaemia.Additional competition could come from Akebia, which has a drug in the ... Astellas Pharma meanwhile has rights to roxadustat in
AZ preps new roxadustat filings, though data foxes investors

Comes with increased blood pressure warning label. AstraZeneca and FibroGen say they are preparing a US filing of roxadustat for anaemia in chronic kidney disease after reporting cardiovascular outcomes data from ... There is a significant unmet medical
First-line ovarian approval cements AZ’s Lynparza lead

And in another positive development, AZ also announced today that two additional phase 3 trials of its just-approved drug for anaemia in chronic kidney disease patients – roxadustat – backed the efficacy
China first market to approve AZ’s kidney drug roxadustat

Roxadustat was compared to treatment with epoetin alfa over 26 weeks, matching the ESA’s efficacy in achieving a significant increase in haemoglobin levels. ... AZ and FibroGen have rights to roxadustat in the US, China and other world markets, while
AZ, FibroGen's anaemia drug on course for first filing this year

Roxadustat works by turning on the body's machinery for producing red blood cells that is usually stimulated by reduced oxygen levels in the blood. ... In addition, use of roxadustat is free of the burden of cold-chain storage and maintaining sterility,

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

Latest Intelligence

Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

The sales forecast for Zolgensma is $2.09bn. Roxadustat, from AstraZeneca, FibroGen and Astellas, targets anaemia in chronic kidney disease (CKD).
China: AstraZeneca’s new engine for growth and innovation

Roxadustat is under accelerated review and, if approved, would also be the first locally- developed medicine to hit the Chinese market even before Europe and the US,” says Mallon. ... Finally, a data readout for roxadustat is expected by the end of 2018

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

New hires at FibroGen, Saniona and Turbine

I am energised to join a company with such an innovative pipeline, as well as the first-in-class asset roxadustat, which has the potential to change the treatment paradigm in

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Emotion-driven clinical trial marketing: A missed opportunity?: Whether we’re conscious of it or not, our emotions play a huge role in day-to-day decision making. Psychological scientists have long explored emotional influences on decision making. Experts like Herbert...
Virtual Hackathon on Healthcare Innovation: a Customer Story: How participants from 9 different countries in the APAC region were brought together to participate in a pharmaceutical company-wide 3-day virtual "hackathon," with spectacular results....
OPEN Health at the World Orphan Drug Conference USA: Our Director of Rare Disease, Gavin Jones looks forward to his conversation with Emily Crossle & Betsy Bogard at #WODCUSA2020 !...